Tenaya Therapeutics to Join TD Cowen Genetic Medicines & RNA Summit

Tenaya Therapeutics, Inc., a biotechnology firm based in South San Francisco, is dedicated to discovering, developing, and delivering therapies that target the root causes of heart disease. On June 18, 2024, the company announced that its CEO, Faraz Ali, will participate in the TD Cowen Genetic Medicines & RNA Summit. This event is scheduled for Friday, June 21, 2024, at 11:20 a.m. Eastern Time. Ali's presentation will be webcast live, accessible through the Investors section of Tenaya’s website. The webcast will be available for replay on Tenaya’s website for 30 days after the conference.

Tenaya Therapeutics focuses on developing therapies aimed at addressing both rare genetic cardiovascular disorders and more common heart conditions. The company leverages its comprehensive Gene Therapy, Cellular Regeneration, and Precision Medicine platforms to drive its innovative pipeline. Among its leading therapeutic candidates are TN-201, TN-401, and TN-301.

TN-201 is a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM), a genetic condition that causes thickening of the heart muscle. TN-401 aims to treat PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), a disorder that affects the heart's rhythm. TN-301, a small molecule HDAC6 inhibitor, is being developed initially for heart failure with preserved ejection fraction (HFpEF), a condition where the heart muscle is stiff and does not fill properly.

Additionally, Tenaya has several early-stage programs that are currently in preclinical development, showcasing the company's commitment to advancing cardiovascular health through innovative therapies.